ATLANTA

QUALITY, INNOVATION, FLEXIBILITY, RESPONSIVENESS

MORE THAN 10 YEARS OF EXPERTISE AT YOUR SERVICE

BONE DISEASE PRECLINICAL CRO

Atlantic Bone Screen

CUSTOM CHEMICAL SYNTHESIS CRO

AtlanChim Pharma

DRUG DISCOVERY COMPANY

ATLANTHERA

OUR CUSTOMERS & MARKETS

ATLANTA HOLDING
3, Rue Aronnax - 44821 Saint-Herblain, Cedex - FRANCE

Atlantic Bone Screen

BONE & JOINT DISEASE PRECLINICAL CRO

Pharma Biotech | Biomaterials | Cosmetics | Food industry | Veterinary

Atlantic Bone Screen aims to **optimize** and **accelerate** the **development of your compounds**, identifying and characterizing the therapeutic potential of your **drug candidates, nutraceuticals and biomaterials**.

- In-vitro assays to evaluate the efficacy and direct/indirect cytotoxicity of your compounds / biomaterials
- In-vivo assays to evaluate the efficacy and toxicity of your compounds / biomaterials
- Histology and histopathology services on any samples/species in oncology, neurology, dermatology, inflammation…
- Imaging services (microCT, DEXA, X-ray…)





www.atlantic-bone-screen.com
contact@atlantic-bone-screen.com / +33 251 789 876

AtlanChim Pharma

CUSTOM CHEMICAL SYNTHESIS CRO

AtlanChim Pharma offers **custom synthesis** of complex small molecules on a laboratory scale from mg to 100g. Through **FFS or FTE** agreements, Atlanchim Pharma provides its pharmaceutical, cosmetic, agrochemical industry customers and biotechnology companies with:

- Custom synthesis
- Site-specific stable isotope labeling
- Isolation and identification of unreferenced impurities
- Analytical services



www.atlanchimpharma.com
contact@atlanchimpharma.com / +33 251 789 876

ATLANTHERA

DRUG DISCOVERY COMPANY - BONE DISEASES

The growing medical need and the **lack of effective treatments for bone tumors** gave rise to Atlanthera.
Atlanthera is a Research and Development company founded in 2011. Specialising in the discovery of innovative molecules for the treatment of bone diseases, Atlanthera has developed a portfolio of new molecules based on the **vectorization of Active Pharmaceutical Ingredients to bone**.
Using this concept, Atlanthera has developed novel treatments that specifically target bone and are able to locally deliver molecules of interest.
4 worldwide patents have been applied for.
Proof of concept has been performed and the **clinical phase is planned for 2017.**

This concept **based on bisphosphonate** (HBP) affinity to bone can also be applied to any treatment focused on bone, for example treating pain, infection, inflammation…

- Osteosarcoma,
- Ewing sarcoma,
- Bone metastases





www.atlanthera.com
contact@atlanthera.com / +33 251 789 876